Diuresis

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

Retrieved on: 
Friday, June 23, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Hypoproteinemia, Organic acid, Heart failure, Urine, Creatinine, Cirrhosis, Dehydration, Tinnitus, Glucose, Deafness, Huber loss, Edema, FTSE Russell, Hepatic encephalopathy, Oliguria, History, Russell Indexes, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Russell, Patient, Urinary retention, Azotemia, Ascites, Coma, Growth, Blood volume, Benign prostatic hyperplasia, Thrombosis, BUN, Cerebral edema, CO2, Anuria, Pharmaceutical industry, Cryptocurrency

The annual Russell indexes reconstitution captures the 3,000 largest US stocks as of April 28, 2023, ranking them by total market capitalization.

Key Points: 
  • The annual Russell indexes reconstitution captures the 3,000 largest US stocks as of April 28, 2023, ranking them by total market capitalization.
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market capitalization rankings and style attributes.
  • Russell indexes are part of FTSE Russell, a leading global index provider.
  • For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website .

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 10, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Medicaid, Hypoproteinemia, Organic acid, Heart failure, AT, Urine, Pharmacy, Creatinine, Cirrhosis, Dehydration, Tinnitus, Glucose, Heart, Deafness, Huber loss, Edema, Food and Drug Administration, Hepatic encephalopathy, Medicare Part D, Prescription, Research, Part, Oliguria, History, Trial of the century, Diuresis, Uric acid, Medicare, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Investment, Physician, Patient, Urinary retention, Azotemia, Ascites, Coma, Blood volume, Benign prostatic hyperplasia, Therapy, Thrombosis, Cerebral edema, BUN, CO2, Conference, Food, Anuria, Security (finance), Pharmaceutical industry, Health insurance, Video game, Medical device, BURLINGTON

BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. 

Key Points: 
  • Ended the first quarter of 2023 with cash, cash equivalents and short-term investments of $116.1 million.
  • Net product revenues were $2.1 million and cost of product revenues were $0.6 million for the first quarter of 2023.
  • Research and development expenses were $2.1 million for the first quarter of 2023, compared to $4.3 million for the first quarter of 2022.
  • As of March 31, 2023, scPharmaceuticals’ total shares outstanding was 35,769,073.
    scPharmaceuticals’ management will host a conference call and webcast to review the Company’s first quarter 2023 results today, Wednesday, May 10, at 4:30 p.m.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 22, 2023
Hypersensitivity, Furosemide, Oaktree Capital Management, NYHA, Congestion, Embolism, Hypoproteinemia, Organic acid, Heart failure, AT, Urine, Marketing, Creatinine, Cirrhosis, Dehydration, Tinnitus, Heart, Glucose, Huber loss, Deafness, Edema, Hepatic encephalopathy, Medicare Part D, Research, Oliguria, History, Diuresis, Uric acid, Medicare, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Patient, Investment, Urinary retention, Azotemia, Ascites, Coma, Blood volume, Benign prostatic hyperplasia, Therapy, Thrombosis, Cerebral edema, BUN, CO2, Conference, Anuria, Pharmaceutical industry, Cryptocurrency, Security (finance), Video game, Finance, BURLINGTON

BURLINGTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2022 and provided a business update. 

Key Points: 
  • Entered into $100 million secured debt financing agreement with funds managed by Oaktree Capital Management in October 2022.
  • scPharmaceuticals ended the fourth quarter 2022 with $118.4 million in cash, cash equivalents, restricted cash and investments, compared to $75.5 million as of December 31, 2021.
    scPharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2022, compared to $7.3 million for the fourth quarter of 2021.
  • Research and development expenses were $2.3 million for the fourth quarter of 2022, compared to $4.5 million for the fourth quarter of 2021.
  • General and administrative expenses were $7.2 million for the fourth quarter of 2022, compared to $2.2 million for the fourth quarter of 2021.

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

Retrieved on: 
Tuesday, February 21, 2023
BUN, Coma, Furosemide, NYHA, Edema, Diuresis, Ascites, Organic acid, Huber loss, Ototoxicity, Deafness, Uric acid, Thrombosis, Erythema, Hepatic encephalopathy, CO2, Patient, Dehydration, Webcast, Urinary retention, Blood volume, Cerebral edema, Creatinine, Kidney, Tinnitus, Hypersensitivity, New York Heart Association Functional Classification, Anuria, Embolism, Oliguria, Hypoproteinemia, Benign prostatic hyperplasia, Urine, Azotemia, Cirrhosis, Glucose, History, Bruise, Congestion, Pharmaceutical industry

FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.

Key Points: 
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • “We are thrilled to announce the commercial availability of FUROSCIX for patients suffering from worsening heart failure due to congestion,” stated John Tucker, Chief Executive Officer of scPharmaceuticals.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

Retrieved on: 
Monday, January 30, 2023
Medicare Part D, Creatinine, Huber loss, Thrombosis, Oliguria, Anuria, Bruise, BUN, Uric acid, Urinary retention, Coma, Medicare, Ascites, Tinnitus, Urine, Organic acid, Hepatic encephalopathy, Benign prostatic hyperplasia, Webcast, History, Furosemide, Deafness, Hypersensitivity, Hypoproteinemia, Medicaid, Commercial, Erythema, New York Heart Association Functional Classification, NYHA, Embolism, Ototoxicity, Patient, CO2, Edema, Congestion, FDA, SVP, Cerebral edema, Azotemia, Cirrhosis, Blood volume, Senior, Kidney, Diuresis, Glucose, Dehydration, Heart failure, Pharmaceutical industry, Medical imaging

“Since obtaining FDA approval for FUROSCIX in October 2022, we have been working tirelessly to prepare for a robust commercial launch, which is targeted for February 20th,” stated John Tucker, Chief Executive Officer.

Key Points: 
  • “Since obtaining FDA approval for FUROSCIX in October 2022, we have been working tirelessly to prepare for a robust commercial launch, which is targeted for February 20th,” stated John Tucker, Chief Executive Officer.
  • Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.
  • In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

Biobeat Demonstrates Prediction Capabilities of Its Devices in Heart Failure Patients under Diuresis

Retrieved on: 
Tuesday, January 17, 2023
Medicine, Prognosis, Heart failure, Health, Patient, PHI, Ambulatory care, HF, Heart, PPG, Medical device, Medical imaging, Diuresis

PETAH TIKVA, Israel, Jan. 17, 2023 /PRNewswire/ -- Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, today announced the publication of clinical data demonstrating that the company's remote patient monitoring wrist device may be utilized for noninvasive wearable multi-parameter monitoring during diuresis in heart failure (HF) patients. The article titled, "Advanced Hemodynamic Monitoring Allows Recognition of Early Response Patterns to Diuresis in Congestive Heart Failure Patients," was published online on December 21, 2022, in the peer-reviewed Journal of Clinical Medicine.

Key Points: 
  • The article titled, " Advanced Hemodynamic Monitoring Allows Recognition of Early Response Patterns to Diuresis in Congestive Heart Failure Patients ," was published online on December 21, 2022, in the peer-reviewed Journal of Clinical Medicine.
  • "Currently, heart failure is a heterogeneous syndrome with no clear guidelines for diuretic administration in heart failure patients' management at home or in ambulatory care.
  • "Data collected from Biobeat's continuous noninvasive wearable multi-parameter monitoring wrist device provides critical insights for clinicians determining the course of treatment and heart failure patient prognosis.
  • This study marks another step toward the implementation of advanced noninvasive hemodynamic monitoring in heart failure patients using Biobeat's technologies."

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

Retrieved on: 
Monday, December 19, 2022
Urine, Ascites, Ototoxicity, Carroll School of Management, NYHA, Congestion, Erythema, Coma, Uric acid, Thrombosis, Sarbanes–Oxley Act, CFO, Huber loss, PricewaterhouseCoopers, Boston College, CO2, Dehydration, Cerebral edema, Anuria, Embolism, Bruise, Patient, Azotemia, Furosemide, Cirrhosis, Benign prostatic hyperplasia, Organic acid, Deafness, Hypoproteinemia, Diuresis, BUN, Heart failure, Edema, Oliguria, Blood volume, History, Hypersensitivity, Bentley University, Glucose, Tinnitus, Senior, Creatinine, Kidney, Urinary retention, Hepatic encephalopathy, New York Heart Association Functional Classification, Pharmaceutical industry, Medical imaging, Finance

BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Rachael Nokes as Chief Financial Officer.

Key Points: 
  • BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Rachael Nokes as Chief Financial Officer.
  • Ms. Nokes previously served as scPharmaceuticals’ Senior Vice President of Finance.
  • “With eight years of exemplary service at the company, I believe Rachael is an outstanding choice for the CFO role as we prepare for the commercial launch of FUROSCIX®,” stated John Tucker, President and Chief Executive Officer of scPharmaceuticals.
  • She joined scPharmaceuticals in 2014 from BG Medicine Inc., a publicly traded medical device company, where she was Director of Accounting.

Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.

Retrieved on: 
Wednesday, November 30, 2022
Cardiology, Biotechnology, Practice Management, Technology, Managed Care, Health, Pharmaceutical, Health Technology, Medical Devices, Telecommunications, Telemedicine, Virtual Medicine, Pillar, Marketing, Diuresis, Heart, Urination, Science, Pharmacy, Business Consulting International, Acceleration, Edema, Risk, Hospital, Physician, MBA, Patient, Heart failure, Strategic planning, Kidney, Drug Quality and Security Act, Health policy, Medicine, MD, Swelling, Health, Security (finance), American University of Integrative Sciences, Quality of life, Consultant, CCI, Abdomen, FDA, Clinical, Pharmaceutical industry, Healthcare

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the Company or Novo), and Clinical Consultants International LLC (CCI), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Agreement (the Agreement) with Sarfez Pharmaceuticals, Inc. (Sarfez), a pharmaceutical research and development company with an FDA-approved edema treatment for patients with heart failure and renal disease.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the Company or Novo), and Clinical Consultants International LLC (CCI), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Agreement (the Agreement) with Sarfez Pharmaceuticals, Inc. (Sarfez), a pharmaceutical research and development company with an FDA-approved edema treatment for patients with heart failure and renal disease.
  • CCI, a Novo wholly owned subsidiary, was established in 2006 in Michigan as a local hospital consulting firm.
  • Headquartered in Boca Raton, Florida, CCI leverages 30+ years of industry experience and its expert consultants worldwide to support clients.
  • Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure

Retrieved on: 
Tuesday, July 12, 2022
Clinical trial, Security (finance), Safety, Infection, Annual report, Tufts University School of Medicine, Solution, Particle-size distribution, Tufts Medical Center, Risk, Diuresis, Weight loss, Patient, Adult, AT, GLOBE, Heart, U.S. Securities and Exchange Commission, COVID-19, NYHA, Heart failure, N-terminal prohormone of brain natriuretic peptide, Private Securities Litigation Reform Act, Death, City centre, Trial of the century, Gauge (instrument), Dehydration, Tufts University School of Dental Medicine, PDUFA, Natriuresis, Quality of life, NDA, Hospital, Congestion, Pharmaceutical industry, Medical imaging, Company, Medicine, BURLINGTON

BURLINGTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) --  scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced positive results from the AT HOME-HF Pilot study, a Phase 2, multicenter, randomized study that compared scPharmaceuticals’ investigational product, FUROSCIX (furosemide 80 mg/10 mL for subcutaneous administration), with a “treatment as usual” approach in chronic heart failure patients presenting to a heart failure clinic with worsening congestion and requiring augmented diuresis.  

Key Points: 
  • There was one serious adverse event (dehydration) that was assessed by the investigator as possibly related to FUROSCIX, which resolved.
  • The AT HOME-HF Pilot study was descriptive only and did not include a powered statistical hypothesis test.
  • The objective of the AT HOME-HF Pilot study was to provide pilot data on the effectiveness and safety of FUROSCIX to inform a potentially larger trial.
  • If approved, FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Retrieved on: 
Tuesday, September 14, 2021
Appropriation, U.S. Department of Defense Strategy for Operating in Cyberspace, CEO, BMI, FDA, University, Health, Forward-looking statement, Center, FAAP, U.S. Department of Veterans Affairs, Office of Inspector General, Adoption, BVA, ASM, University of Tennessee Health Science Center, Private Securities Litigation Reform Act, DXR, Defense, Blood volume, Risk, National Institutes of Health Clinical Center, Ultrafiltration, NIH, FAHA, Veterans' affairs, NYSE, Physician, Heart failure, MD, Volume overload, Heart Failure Society of America, Phenotype, Contract, Critical care, MPH, GLOBE, Anemia, Population, FHFS, Face, Diuresis, Veteran, SEC, FACC, National Institute, LVAD, Medical imaging, Medical device, Pharmaceutical industry

“The data we regularly collect on use of the BVA-100 test consistently demonstrates that it provides the most accurate and reliable methodology to both personalize and optimize treatment in heart failure patients,” added Mr. Feldschuh. “We are encouraged by the growing recognition of the significant value and clinical adoption of the BVA-100 test to improve both clinical and economic outcomes -- we look forward to providing updates on these outstanding results.”

Key Points: 
  • Volume-Guided Venous to Venous Ultrafiltration in Hospitalized Heart Failure Patients: This pilot study combined blood volume analysis and ultrafiltration to safely remove fluid with volume overload.
  • Study authors indicated that earlier utilization of the BVA-100 test may have prevented the acute renal injury from their previous diuresis.
  • This study also measures the benefit of the BVA-100 test for improving ambulatory heart failure patient care, a population that numbers more than 6 million in the U.S. alone.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.